Fredrik Henell is the CEO of Axcentua Pharmaceuticals. He spent close to 20 years with Pharmacia and predecessor companies, primarily in Business Development roles in Europe (Sweden, Italy and France) and the US. He held similar roles in the US biotech industry (ZymoGenetics) as well as the generic industry (Hospira, Europe). Fredrik received an MBA from the Stockholm School of Economics and an MD and a PhD from the Karolinska Institutet, Stockholm, Sweden.
Anders Berkenstam is the CSO of the Company. He is also a founder and Board member. Following an academic career with publications in peer reviewed scientific journals (Cell, Nature and EMBO Journal) Anders joined Pharmacia in 1996. He subsequently held positions of increasing responsibility in biotech and in pharmaceutical companies. It culminated when he in 2002 became the Vice President of Research & Development at Karo Bio AB, Sweden. During his tenure with the company he successfully shepherded the company’s lead compound into proof-of-concept phase I clinical studies. Anders previously also held a position as Associate Professor at The Methodist Hospital Research Institute, Houston, Texas and is developing novel treatments for neurodegenerative diseases. Anders earned his PhD from the Karolinska Institute, Sweden
Ronny Westberg is the CEO of RW Clinical Trials AB. Before starting his consulting company i year 2000, Ronny held several positions within Bristol-Myers Squibb´s oncology deparment for approximately 15 years. The last 5 years as Assistant Medical Director Oncology – Central and Eastern Europe. During these years Ronny was heavily involved in the companys clinical development portfolio in oncology . Ronny has been retained as Axcentua´s consultant in regards of the company´s clinical development program in pancreatic cancer.